comparemela.com

Latest Breaking News On - Health biotech - Page 16 : comparemela.com

Insights on the Camphor Tablets Global Market to 2030 - Featuring Beijing Herbal Health Biotech, Benefont, Fujian Green Pine and Hiya International Among Others

/PRNewswire/ The "Camphor Tablets Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and.

Beijing
China
Fujian
United-states
India
Canada
United-kingdom
Dublin
Ireland
America
Jadran-galenski-laboratorij
Asia-pacific

How Manitoba's bioscience sector flies under the radar

How Manitoba's bioscience sector flies under the radar
winnipeg.ctvnews.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from winnipeg.ctvnews.ca Daily Mail and Mail on Sunday newspapers.

Canada
Kim-kline
Melanie-hiebert
Stephanie-haverstick
Health-biotech
Walmart
Kline
Bioscience-association-of-manitoba
Emergent-biosolution-winnipeg
Clean-biotech
Biosolution-winnipeg
Life-brand

9 drugs produced in Himachal fail safety test

Nine medicine samples manufactured by various pharmaceutical firms in Himachal Pradesh are among 50 drugs declared substandard nationwide by the Central Drugs Standard Control Organisation (CDSCO) in its monthly alert issued today.

Paonta-sahib
Himachal-pradesh
India
Kala-amb
Nalagarh
Navneet-marwaha
Healcure-lifesciences
Ambika-sharma
Pushkar-pharma
Health-biotech
Salus-pharmaceuticals
Lifesciences-india-ltd

9 drugs made in Himachal Pradesh lose safety checks

Various reasons such as description, power of hydrogen (pH), presence of particulate matter, sterility, dissolution, fineness of dispersion and disintegration have been stated as the reasons for failure. Navneet Marwaha, State Drugs Controller, said the batches declared substandard would be immediately withdrawn from the market. He said show-cause notices had been issued to all firms and the drug inspectors had been directed to inquire whether the conditions to issue licence were being adhered to. Further action as per the findings would be undertaken, he said. Among the pharmaceutical units, Zee Laboratories (Paonta Sahib) had repetitively figured on the list. Assistant Drugs Controller (Paonta Sahib) Sunny Kaushal said actions such as suspension and withdrawal of product permissions had been taken over the past few months when the company’s samples failed.

Paonta-sahib
Himachal-pradesh
India
Kala-amb
Nalagarh
Healcure-lifesciences
Riya-girdhar
Pushkar-pharma
Health-biotech
Salus-pharmaceuticals
Lifesciences-india-ltd
Central-drugs-standard-control-organization

Appendix 4C - Q1 FY23 Quarterly Cash Flow Report

First patient dosed in Phase 2 clinical trial for ATH434 in New Zealand, trial opens in Europe and AustraliaApproval of Investigational New Drug a.

Italy
Melbourne
Victoria
Australia
United-states
New-zealand
United-kingdom
California
San-francisco
Italian
American
David-stamler

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.